On Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to ...

The familial trend, it turned out, was linked to a genetic mutation. That meant Bill might also be at risk for the disease.

Explore how the genetic testing industry is transforming healthcare through precision medicine ensuring patient privacy and ...

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire ...

Orange County’s third largest medical diagnostics and testing company is being acquired by a fast-growing Chicago-based firm ...

DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company will ...

We recently published a list of UBS’ Top Quant Stocks In AI, IT, Healthcare & Other Sectors: Top 33 Stocks In All Sectors. In ...

The global market for cancer-focused genetic testing services is on a transformative growth trajectory, with projections estimating a market size of USD 8,472.70 million by 2024, and an expected ...

Customers of Atlas Biomed are angry and worried about what's happened to the highly sensitive data they shared.

Tempus AI agreed to buy genetic testing company Ambry Genetics for $375 million in cash and $225 million in shares. Chicago-based Tempus, which makes AI-enabled precision medicine solutions, said the ...